Summary
Oral tropisetron, a 5-hydroxytryptamine type 3 (serotonin3) [5-HT3]-receptor antagonist, at a dose of 5mg daily was evaluated as antiemetic prophylaxis during postoperative abdominal irradiation. 20 women with International Federation of Gynecology and Obstetrics (FIGO) stage I to III ovarian carcinoma were included. 12 women received irradiation of whole abdominal fields and 8 of lower abdominal/pelvic fields. Efficacy and adverse events were recorded by the patients in diary-form booklets. The cumulative weekly incidence of patients with nausea, which was generally mild and of short duration, increased from 30% at the start of radiotherapy to 54% at the end of treatment. Episodes of vomiting occurred in less than 10% of the patients. Diarrhoea was common towards the end of the radiotherapy courses, and the proportion of patients needing extra antidiarrhoeal medication (loperamide) increased from 38% during the first week to 100% at the end of the radiotherapy course. Mean weight loss was 1.2kg during the 5- to 6-week course. Overall ratings for quality of life were excellent or good in 75 to 85% of patients. Tropisetron seems to be a promising and well tolerated drug in conjunction with extended radiotherapy of abdominal fields. This was an open study, establishing the methodology for long term follow-up of patients during fractionated radiotherapy.
Similar content being viewed by others
References
Cunningham D, Pople A, Ford HT, et al. Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5 HT3 receptor antagonist. Lancet 1: 1461–1463, 1987
Danjoux CE, Rider WD, Fitzpatrick PJ. The acute radiation syndrome: a memorial to William Michael Court-Brown. Clinical Radiology 30: 581–584, 1979
Franzén L, Lomberg H, Israelsson G, et al. Ondansetron-Nytt antiemetikum mot illamående i samband med strålterapi. Svenska Läkarsällskapets Handlingar Hygiea 99: 255–256, 1990
Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. New England Journal of Medicine 324: 709–715, 1991
Marty M, Pouillart P, Scholl S, Droz JP, Azab M, et al. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. New England Journal of Medicine 322: 816–821, 1990
Priestman T, Priestman S. An initial evaluation of nabilone in the control of radiotherapy-induced nausea and vomiting. Clinical Radiology 35: 265–266, 1984
Reyntjens A. Domperidone as an anti-emetic: summary of research reports. Postgraduate Medical Journal 55(Suppl. 1): 50–54, 1979
Richardson BP, Buchheit KH. The pharmacology, distribution and function of 5-HT3 receptors. In Osborne NN & Hamon M (Eds) Neuronal serotonin, pp. 465–504, Wiley and Sons Ltd, London, 1988
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sorbe, B., Berglind, AM. Tropisetron, a New 5-HT3-Receptor Antagonist, in the Prevention of Radiation-Induced Nausea, Vomiting and Diarrhoea. Drugs 43 (Suppl 3), 33–39 (1992). https://doi.org/10.2165/00003495-199200433-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199200433-00008